Description
NRG-BR008 (HERO): A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer
This trial is availableat multiple Sutter locations. Please contact one of the following about the study:
Site Point of Contacts
Alta Bates (CA164)
Painte’ Berniard Piante.Berniard@sutterhealth.org
California Pacific Medical Center (CA222)
Sophia Vu (Manager) Sophia.Vue@sutterhealth.org
Eden Medical Center (CA200)
Leah Galvez Leah.Galvez@sutterhealth.org
Mills Health Center (CA209)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
Memorial Medical Center (CA182)
Kristen Moorman Kristen.Moorman@sutterhealth.org
Palo Alto Medical Foundation (PAMF – All sites)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
SIMR Sutter Institute for Medical Research (SIMR – All sites)
Kirsten Babski Kirsten.Babski@sutterhealth.org
Sutter Cancer Research Consortium
NCIClinicalTrials@sutterhealth.org
Principal Investigator
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS